Litfulo

Generic name: Ritlecitinib
Dosage form: oral capsule
Drug class: Multikinase inhibitors

Usage of Litfulo

Litfulo (ritlecitinib) is an oral, once-daily prescription treatment for severe alopecia areata in adults and adolescents aged 12 and older.

Alopecia areata is an autoimmune disease characterized by patchy hair loss, usually on the scalp but occasionally on the face (eyebrows, eyelashes, beard) and other body areas. It is caused by the body’s immune system attacking healthy hair follicles, which causes the hair to fall out.

Litfulo works by selectively and irreversibly inhibiting Janus kinase 3 (JAK3), and other tyrosine kinases, and inhibits cytokine-induced STAT phosphorylation mediated by JAK3-dependent receptors. In addition, it inhibits the signaling of immune receptors dependent on TEC kinase family members. Alopecia areata is characterized by the deregulation of JAK/STAT activity, and the actions of Lifulo are thought to inhibit the function of signaling molecules and immune cells associated with hair loss in alopecia areata.

Litfulo was approved on June 23, 2023, and was the first treatment to be approved for adolescents as well as adults with alopecia areata. It belongs to the class of medicines known as covalent kinase inhibitors.

Litfulo side effects

The most common side effects are:

  • headache
  • diarrhea
  • acne
  • rash
  • urticaria
  • folliculitis
  • fever
  • atopic dermatitis
  • dizziness
  • increases in laboratory values of creatine phosphokinase and decreases in red blood cell counts
  • mouth ulcers.

    • Before taking Litfulo

    You should not use Litfulo if you are allergic to ritlecitinib or any of the inactive ingredients in the capsule. Discontinue if a clinically significant hypersensitivity reaction occurs.

    Taking Litfulo can increase your risk of life-threatening medical problems, including serious infections, a heart attack or stroke, blood clots, or cancer. Tell your doctor if you've had:

  • a weak immune system or chronic infection (such as tuberculosis, shingles, HIV, or hepatitis)
  • any type of cancer
  • chronic lung disease
  • heart problems
  • a heart attack, stroke, or blood clot
  • liver disease
  • if you've ever smoked
  • if you are scheduled to receive any vaccine.

    • Tell your doctor if you've been sick with signs of infection, such as fever, chills, muscle aches, cough, trouble breathing, skin sores, diarrhea, or painful urination.

    Tell your doctor if you've had or been exposed to tuberculosis, or if you recently traveled. Some infections are more common in certain parts of the world, and you may have been exposed during travel.

    Your doctor will order some blood tests before starting Litfulo to check for any laboratory abnormalities. Your treatment may be interrupted or discontinued if any of these occur, such as significant decreases in lymphocyte or platelet counts occur.

    Using this medicine may increase your risk of developing certain cancers, such as lymphoma or lung cancer. Ask your doctor about this risk.

    Children

    The safety of Litfulo in children under 12 years of age has not been established.

    Pregnancy

    Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm an unborn baby. If you inadvertently become pregnant ask your healthcare providers to ring 1-877-390-2940.

    Breastfeeding

    Tell your doctor if you are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Litfulo and for approximately 14 hours after the last dose.

    Relate drugs

    Warnings

    Litfulo is associated with an increased risk of serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death, including tuberculosis (TB). Litfulo should not be started in those with active TB or a serious infection. Investigations for latent TB should be undertaken before and during therapy and treatment started and the infection cleared before starting Litfulo. All patients should be monitored for signs and symptoms of infection, including TB, during and after treatment.

    Janus kinase inhibitors, such as Litfulo are associated with a higher rate of all-cause mortality, including sudden cardiovascular death, myocardial infarction, and stroke, compared to other medications, such as TNF blockers. Thrombosis has occurred in patients treated with Litfulo and there is a higher risk of pulmonary embolism, and venous and arterial thrombosis with JAK inhibitors versus other medications.

    Higher rates of malignancies, including non-melanoma skin cancer (NMSC), and lymphoma have been observed in clinical trials of Litfulo, compared to those treated with other medications. Higher rates of lung cancer and all types of malignancies were observed in current or past smokers treated with Litfulo. Consider the risks and benefits of treatment with ritlecitinib in those with a known malignancy other than a successfully treated NMSC or cervical cancer. Periodic skin examinations are recommended for patients who are at increased risk for skin cancer.

    Should not be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

    Not recommended in severe liver disease.

    What other drugs will affect Litfulo

    Tell your doctor about all your other medicines, especially:

  • CYP3A substrates (such as acetaminophen, codeine, ciclosporin, Diazepam, and erythromycin)
  • CYP3A inducers (such as rifampicin)
  • CYP1A2 substrates, such as caffeine, clozapine, tacrine, propranolol, and mexiletine.

    • Should not be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

    This list is not complete. Other drugs may affect Litfulo, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords